Are measurements of urine enzymes useful during aminoglycoside therapy?

Michael D. Reed, Mary W. Vermeulen, Robert C. Stern, P. W. Cheng, Stephen H. Powell, Thomas F. Boat

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We prospectively evaluated concentrations of β-D-galactosid- ase, α-L-fucosidase, β-D-N-acetylglucosaminidase, and lysozyme in urine from normal subjects, ambulatory patients with cystic fibrosis (CF), and CF patients with previously normal renal function who were receiving intravenous aminoglycoside (AG) therapy. Enzyme activities were generally low or negligible in subjects not receiving AG. Enzymuria was documented during 12 of 13 AG treatment courses and most frequently involved β-D-N-acetylglu- cosaminidase excretion. In nine courses, enzymuria occurred in the absence of proteinuria or elevations of blood urea nitrogen and serum creatinine. In three courses attended by enzymuria and evidence of nephrotoxicity, neither the time of appearance nor the magnitude of enzymuria was different from that of nonnephrotoxic patients. In two of these three treatment courses, enzymuria preceded clinical evidence of nephrotoxicity by 16 and 5 days, and in the third course enzymuria and elevation of blood urea nitrogen and serum creatinine occurred simultaneously. We conclude that enzymuria is not a reliable predictor of nephrotoxicity due to AG in CF patients and is not an indication to discontinue AG therapy. Speculation: Measurement of urinary enzyme excretion after aminoglycoside therapy appears to be too sensitive a test to be clinically useful as a predictor of aminoglycoside-associated nephrotoxicity in patients with cystic fibrosis.

Original languageEnglish (US)
Pages (from-to)1234-1239
Number of pages6
JournalPediatric Research
Volume15
Issue number9
DOIs
StatePublished - Sep 1981

Fingerprint

Aminoglycosides
Urine
Cystic Fibrosis
Enzymes
Acetylglucosaminidase
Blood Urea Nitrogen
Therapeutics
Creatinine
Galactosidases
alpha-L-Fucosidase
Muramidase
Serum
Proteinuria
Kidney

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Reed, M. D., Vermeulen, M. W., Stern, R. C., Cheng, P. W., Powell, S. H., & Boat, T. F. (1981). Are measurements of urine enzymes useful during aminoglycoside therapy? Pediatric Research, 15(9), 1234-1239. https://doi.org/10.1203/00006450-198109000-00002

Are measurements of urine enzymes useful during aminoglycoside therapy? / Reed, Michael D.; Vermeulen, Mary W.; Stern, Robert C.; Cheng, P. W.; Powell, Stephen H.; Boat, Thomas F.

In: Pediatric Research, Vol. 15, No. 9, 09.1981, p. 1234-1239.

Research output: Contribution to journalArticle

Reed, MD, Vermeulen, MW, Stern, RC, Cheng, PW, Powell, SH & Boat, TF 1981, 'Are measurements of urine enzymes useful during aminoglycoside therapy?', Pediatric Research, vol. 15, no. 9, pp. 1234-1239. https://doi.org/10.1203/00006450-198109000-00002
Reed, Michael D. ; Vermeulen, Mary W. ; Stern, Robert C. ; Cheng, P. W. ; Powell, Stephen H. ; Boat, Thomas F. / Are measurements of urine enzymes useful during aminoglycoside therapy?. In: Pediatric Research. 1981 ; Vol. 15, No. 9. pp. 1234-1239.
@article{68aa63383ccd4eafb230c04222d27285,
title = "Are measurements of urine enzymes useful during aminoglycoside therapy?",
abstract = "We prospectively evaluated concentrations of β-D-galactosid- ase, α-L-fucosidase, β-D-N-acetylglucosaminidase, and lysozyme in urine from normal subjects, ambulatory patients with cystic fibrosis (CF), and CF patients with previously normal renal function who were receiving intravenous aminoglycoside (AG) therapy. Enzyme activities were generally low or negligible in subjects not receiving AG. Enzymuria was documented during 12 of 13 AG treatment courses and most frequently involved β-D-N-acetylglu- cosaminidase excretion. In nine courses, enzymuria occurred in the absence of proteinuria or elevations of blood urea nitrogen and serum creatinine. In three courses attended by enzymuria and evidence of nephrotoxicity, neither the time of appearance nor the magnitude of enzymuria was different from that of nonnephrotoxic patients. In two of these three treatment courses, enzymuria preceded clinical evidence of nephrotoxicity by 16 and 5 days, and in the third course enzymuria and elevation of blood urea nitrogen and serum creatinine occurred simultaneously. We conclude that enzymuria is not a reliable predictor of nephrotoxicity due to AG in CF patients and is not an indication to discontinue AG therapy. Speculation: Measurement of urinary enzyme excretion after aminoglycoside therapy appears to be too sensitive a test to be clinically useful as a predictor of aminoglycoside-associated nephrotoxicity in patients with cystic fibrosis.",
author = "Reed, {Michael D.} and Vermeulen, {Mary W.} and Stern, {Robert C.} and Cheng, {P. W.} and Powell, {Stephen H.} and Boat, {Thomas F.}",
year = "1981",
month = "9",
doi = "10.1203/00006450-198109000-00002",
language = "English (US)",
volume = "15",
pages = "1234--1239",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Are measurements of urine enzymes useful during aminoglycoside therapy?

AU - Reed, Michael D.

AU - Vermeulen, Mary W.

AU - Stern, Robert C.

AU - Cheng, P. W.

AU - Powell, Stephen H.

AU - Boat, Thomas F.

PY - 1981/9

Y1 - 1981/9

N2 - We prospectively evaluated concentrations of β-D-galactosid- ase, α-L-fucosidase, β-D-N-acetylglucosaminidase, and lysozyme in urine from normal subjects, ambulatory patients with cystic fibrosis (CF), and CF patients with previously normal renal function who were receiving intravenous aminoglycoside (AG) therapy. Enzyme activities were generally low or negligible in subjects not receiving AG. Enzymuria was documented during 12 of 13 AG treatment courses and most frequently involved β-D-N-acetylglu- cosaminidase excretion. In nine courses, enzymuria occurred in the absence of proteinuria or elevations of blood urea nitrogen and serum creatinine. In three courses attended by enzymuria and evidence of nephrotoxicity, neither the time of appearance nor the magnitude of enzymuria was different from that of nonnephrotoxic patients. In two of these three treatment courses, enzymuria preceded clinical evidence of nephrotoxicity by 16 and 5 days, and in the third course enzymuria and elevation of blood urea nitrogen and serum creatinine occurred simultaneously. We conclude that enzymuria is not a reliable predictor of nephrotoxicity due to AG in CF patients and is not an indication to discontinue AG therapy. Speculation: Measurement of urinary enzyme excretion after aminoglycoside therapy appears to be too sensitive a test to be clinically useful as a predictor of aminoglycoside-associated nephrotoxicity in patients with cystic fibrosis.

AB - We prospectively evaluated concentrations of β-D-galactosid- ase, α-L-fucosidase, β-D-N-acetylglucosaminidase, and lysozyme in urine from normal subjects, ambulatory patients with cystic fibrosis (CF), and CF patients with previously normal renal function who were receiving intravenous aminoglycoside (AG) therapy. Enzyme activities were generally low or negligible in subjects not receiving AG. Enzymuria was documented during 12 of 13 AG treatment courses and most frequently involved β-D-N-acetylglu- cosaminidase excretion. In nine courses, enzymuria occurred in the absence of proteinuria or elevations of blood urea nitrogen and serum creatinine. In three courses attended by enzymuria and evidence of nephrotoxicity, neither the time of appearance nor the magnitude of enzymuria was different from that of nonnephrotoxic patients. In two of these three treatment courses, enzymuria preceded clinical evidence of nephrotoxicity by 16 and 5 days, and in the third course enzymuria and elevation of blood urea nitrogen and serum creatinine occurred simultaneously. We conclude that enzymuria is not a reliable predictor of nephrotoxicity due to AG in CF patients and is not an indication to discontinue AG therapy. Speculation: Measurement of urinary enzyme excretion after aminoglycoside therapy appears to be too sensitive a test to be clinically useful as a predictor of aminoglycoside-associated nephrotoxicity in patients with cystic fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=0019408097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019408097&partnerID=8YFLogxK

U2 - 10.1203/00006450-198109000-00002

DO - 10.1203/00006450-198109000-00002

M3 - Article

C2 - 6793992

AN - SCOPUS:0019408097

VL - 15

SP - 1234

EP - 1239

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 9

ER -